# US 11,998,757 B2 · Far red and near infrared light-mediated conditioning of tissues and/or blood to prevent reperfusion injury in endovascular therapies > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,998,757 B2 - Document ID: US11998757B2 - Status: Granted - Kind: B2 - Application number: 17/701,099 - Filed: 2022-03-22 - Published: 2022-09-29 - Granted: 2024-06-04 - Earliest claimed: 2021-03-23 - Assignees: The Medical College of Wisconsin, Inc. - Applicants: The Medical College of Wisconsin, Inc. - Inventors: Nicole Lohr; Michael Salinger - Web page: https://patentgrep.com/patent/US11998757B2 ## CPC - A61N 5/0601: {Apparatus for use inside the body} - A61B 18/24: with a catheter (A61B18/26, A61B18/28 take precedence) - A61N 5/0613: {Apparatus adapted for a specific treatment} - A61B 2017/0019: {Means for setting or varying the pulse width} - A61B 2018/00351: {Heart} - A61B 2018/00577: {Ablation} - A61B 2090/049: {against light, e.g. laser} - A61N 2005/0602: {for treatment of blood vessels} - A61N 2005/063: {comprising light transmitting means, e.g. optical fibres} - A61N 2005/0651: {Diodes} - A61N 2005/0662: {Visible light} - A61N 2005/0663: {Coloured light} - A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B) - A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D) ## Abstract Reperfusion injury is limited during endovascular therapies (e.g., revascularization and/or reperfusion of end organ tissues) by conditioning the tissues against reperfusion injury using an optical fiber catheter to deliver far red and near infrared (R/NIR) light to the tissues. The light may be multiple wavelength or single wavelength light, and may have one or more wavelengths selected from the range of 510 to 830 nm. The R/NIR light may be delivered concurrently with the endovascular therapy, or in other instances may be delivered before or after a particular therapy. ## Claims ### Claim 1 A method for conditioning at least one of tissues or blood to reduce reperfusion injury, the method comprising: (a) providing an optical fiber catheter to a region in a subject containing tissues; (b) conditioning the at least one of tissues or blood in the region to reduce reperfusion injury by operating a light source coupled to a proximal end of the optical fiber catheter to generate light having at least one wavelength selected from a range of 510 nanometers (nm) to 670 nm, such that the light is communicated from the proximal end of the optical fiber catheter to its distal tip where the light is emitted from the optical fiber catheter and caused to impinge upon the at least one of tissues or blood in the region; (c) administering an endovascular therapy to the at least one of tissues or blood in the region; and wherein the at least one of tissues or blood in the region are conditioned by the light emitted from the optical fiber such that reperfusion injury of the tissues resulting from the endovascular therapy is significantly reduced. ### Claim 2 (depends on 1) The method of claim 1, wherein the light source is a laser light source and the light is laser light having a single wavelength selected from the range of 510 nm to 670 nm. ### Claim 3 (depends on 2) The method of claim 2, wherein the laser light has a single wavelength of 670 nm. ### Claim 4 (depends on 1) The method of claim 1, wherein the light is generated and delivered to the tissues in the region concurrently with the endovascular therapy. ### Claim 5 (depends on 4) The method of claim 4, wherein the tissues in the region include myocardial tissues. ### Claim 6 (depends on 5) The method of claim 5, wherein the endovascular therapy comprises an ST-elevation myocardial infarction (STEMI) reperfusion therapy. ### Claim 7 (depends on 1) The method of claim 1, wherein the endovascular therapy comprises laser ablation therapy of the tissues in the region. ### Claim 8 (depends on 7) The method of claim 7, wherein the laser ablation therapy is administered with an excimer laser source coupled to the optical fiber catheter. ### Claim 9 (depends on 1) The method of claim 1, wherein the light is generated and delivered in a continuous delivery. ### Claim 10 (depends on 1) The method of claim 1, wherein the light is generated and delivered in a pulsed delivery, such that the light is generated and delivered in a series of pulses at a pulse rate selected from a range of 25 Hertz (Hz) to 80 Hz. ### Claim 11 (depends on 10) The method of claim 10, wherein each pulse in the series of pulses has a pulse width selected from a range of 125 nanoseconds (ns) to 200 ns. ### Claim 12 (depends on 1) The method of claim 1, wherein the light is generated with an intensity in a range of 25 mW/cm2 and 170 mW/cm2. ### Claim 13 (depends on 12) The method of claim 12, wherein the light is generated with an intensity of 50 mW/cm2 for a duration of time in a range of 5 minutes to 10 minutes. ### Claim 14 A method for conditioning at least one of tissues or blood to reduce reperfusion injury, the method comprising: (a) providing a transdermal light source to a skin surface of a subject; (b) conditioning the at least one of tissues or blood in a subdermal region to reduce reperfusion injury by operating the transdermal light source to generate light having at least one wavelength selected from a range of 510 nanometers (nm) to 670 nm, such that the light is emitted from the transdermal light source and caused to impinge upon the at least one of tissues or blood in the subdermal region; (c) administering an endovascular therapy to the at least one of tissues or blood in the region; and wherein the at least one of tissues or blood in the subdermal region are conditioned by the light emitted from the transdermal light source such that reperfusion injury of the tissues resulting from the endovascular therapy is significantly reduced. ### Claim 15 (depends on 14) The method of claim 14, wherein the light source is a laser light source and the light is laser light having a single wavelength selected from the range of 510 nm to 670 nm. ### Claim 16 (depends on 15) The method of claim 15, wherein the laser light has a single wavelength of 670 nm. ### Claim 17 (depends on 14) The method of claim 14, wherein the light is generated and delivered to the tissues in the region concurrently with the endovascular therapy. ### Claim 18 (depends on 14) The method of claim 14, wherein the light is generated with an intensity in a range of 25 mW/cm2 and 170 mW/cm2. ### Claim 19 (depends on 18) The method of claim 18, wherein the light is generated with an intensity of 50 mW/cm2 for a duration of time in a range of 5 minutes to 10 minutes. ### Claim 20 (depends on 14) The method of claim 14, wherein the light is generated with an output fluence of 22.5 J/cm2, such that the light is delivered to a depth between 15 mm and 20 mm. ### Claim 21 (depends on 14) The method of claim 14, wherein the light source is a light emitting diode (LED) light source.